| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
| | | | | | | Fair Value Measurements at | |
| | | | | | | June 30, 2024 | |
| | | | | | | Quoted | | | Significant | | | | | |
| | | | | | | Prices | | | Other | | | Significant | |
| | | | | | | in Active | | | Observable | | | Unobservable | |
| | | | | | | Markets | | | Inputs | | | Inputs | |
| | | Total | | | (Level 1) | | | (Level 2) | | | (Level 3) | |
| Assets: | | | | | | | | | | | | | | | | |
| Stock held by GenMat advances (see Note 3) | | $ | 412,206 | | | $ | — | | | $ | 412,206 | | | $ | — | |
| | | | | | | | | | | | | | | | | |
| Liabilities: | | | | | | | | | | | | | | | | |
| Kips Bay convertible debt derivative | | $ | 470,000 | | | $ | — | | | $ | — | | | $ | 470,000 | |
| LINICO related derivative | | | 3,252,429 | | | | — | | | | 3,252,429 | | | | — | |
| Haywood derivative | | | 678,150 | | | | — | | | | 678,150 | | | | — | |
| Total liabilities measured at fair value | | $ | 4,400,579 | | | $ | — | | | $ | 3,930,579 | | | $ | 470,000 | |
| | | | | | | Fair Value Measurements at | |
| | | | | | | December 31, 2023 | |
| | | | | | | Quoted | | | Significant | | | | | |
| | | | | | | Prices | | | Other | | | Significant | |
| | | | | | | in Active | | | Observable | | | Unobservable | |
| | | | | | | Markets | | | Inputs | | | Inputs | |
| | | Total | | | (Level 1) | | | (Level 2) | | | (Level 3) | |
| Liabilities: | | | | | | | | | | | | | | | | |
| Kips Bay convertible debt derivative | | $ | 1,360,000 | | | $ | — | | | $ | — | | | $ | 1,360,000 | |
| LINICO related derivative | | | 2,383,162 | | | | — | | | | 2,383,162 | | | | — | |
| Haywood derivative | | | 875,000 | | | | — | | | | 875,000 | | | | — | |
| GenMat derivative | | | 781,966 | | | | — | | | | 781,966 | | | | — | |
| Total liabilities measured at fair value | | $ | 5,400,128 | | | $ | — | | | $ | 4,040,128 | | | $ | 1,360,000 | |
|
| Schedule of Derivative Liabilities at Fair Value [Table Text Block] |
| | | For the Three-Months Ended June 30, 2024 | |
| | | As of March 31, 2024 | | | (Additions) Deductions | | | Unrealized Gain (Loss) on Change in Fair Value | | | Payments for Decrease in Contractual Stock Consideration | | | As of June 30, 2024 | |
| Kips Bay convertible debt derivative | | $ | (1,440,000 | ) | | $ | 430,520 | | | $ | 539,480 | | | $ | — | | | $ | (470,000 | ) |
| LINICO related derivative | | | (2,893,325 | ) | | | — | | | | (359,104 | ) | | | — | | | | (3,252,429 | ) |
| Haywood derivative | | | (1,160,000 | ) | | | 409,850 | | | | (48,000 | ) | | | 120,000 | | | | (678,150 | ) |
| GenMat derivative | | | 240,478 | | | | (694,970 | ) | | | (209,872 | ) | | | 664,364 | | | | — | |
| Total derivative liabilities measured at fair value | | $ | (5,252,847 | ) | | $ | 145,400 | | | $ | (77,496 | ) | | $ | 784,364 | | | $ | (4,400,579 | ) |
| | | For the Six-Months Ended June 30, 2024 | |
| | | As of December 31, 2023 | | | (Additions) Deductions | | | Unrealized Gain (Loss) on Change in Fair Value | | | Payments for Decrease in Contractual Stock Consideration | | | As of June 30, 2024 | |
| Kips Bay convertible debt derivative | | $ | (1,360,000 | ) | | $ | (166,081 | ) | | $ | 1,056,081 | | | $ | — | | | $ | (470,000 | ) |
| LINICO related derivative | | | (2,383,162 | ) | | | — | | | | (869,267 | ) | | | — | | | | (3,252,429 | ) |
| Haywood derivative | | | (875,000 | ) | | | 409,850 | | | | (333,000 | ) | | | 120,000 | | | | (678,150 | ) |
| GenMat derivative | | | (781,966 | ) | | | (694,970 | ) | | | (687,428 | ) | | | 2,164,364 | | | | — | |
| Total derivative liabilities measured at fair value | | $ | (5,400,128 | ) | | $ | (451,201 | ) | | $ | (833,614 | ) | | $ | 2,284,364 | | | $ | (4,400,579 | ) |
| | | For the Three-Months Ended June 30, 2023 | |
| | | As of March 31, 2023 | | | (Additions) Deductions | | | Unrealized Gain (Loss) on Change in Fair Value | | | Payments for Decrease in Contractual Stock Consideration | | | As of June 30, 2023 | |
| Ionic convertible debt derivative | | $ | (24,000 | ) | | $ | 840,254 | | | $ | (1,416,254 | ) | | $ | — | | | $ | (600,000 | ) |
| LINICO related derivative | | | (5,468,162 | ) | | | — | | | | 1,365,000 | | | | 825,000 | | | | (3,278,162 | ) |
| Haywood derivative | | | (1,190,000 | ) | | | — | | | | 585,000 | | | | — | | | | (605,000 | ) |
| GenMat derivative | | | (5,234,043 | ) | | | — | | | | 1,030,871 | | | | 900,000 | | | | (3,303,172 | ) |
| Total derivative liabilities measured at fair value | | $ | (11,916,205 | ) | | $ | 840,254 | | | $ | 1,564,617 | | | $ | 1,725,000 | | | $ | (7,786,334 | ) |
| | | For the Six-Months Ended June 30, 2023 | |
| | | As of December 31, 2022 | | | (Additions) Deductions | | | Unrealized Gain (Loss) on Change in Fair Value | | | Payments for Decrease in Contractual Stock Consideration | | | As of June 30, 2023 | |
| Ionic convertible debt derivative | | $ | (420,000 | ) | | $ | 996,254 | | | $ | (1,176,254 | ) | | $ | — | | | $ | (600,000 | ) |
| LINICO related derivative | | | (6,053,162 | ) | | | — | | | | 1,575,000 | | | | 1,200,000 | | | | (3,278,162 | ) |
| Haywood derivative | | | (1,480,000 | ) | | | — | | | | 675,000 | | | | 200,000 | | | | (605,000 | ) |
| GenMat derivative | | | (6,592,638 | ) | | | — | | | | 1,189,466 | | | | 2,100,000 | | | | (3,303,172 | ) |
| Total derivative liabilities measured at fair value | | $ | (14,545,800 | ) | | $ | 996,254 | | | $ | 2,263,212 | | | $ | 3,500,000 | | | $ | (7,786,334 | ) |
|